Company: Kazia Therapeutics Limited
Job title: Chief Executive Officer & Managing Director
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation. He has been responsible for several large-scale international clinical programs, and for numerous product approvals in multiple countries.
Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Kazia Therapeutics in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore. Dr Garner is a member of the Australian Institute of Company Directors.
Study PI3K as a Key Target in Glioblastoma 2:15 pm
Explore opportunities and challenges associated with modulating PI3K as a therapeutic strategy in glioblastoma Examine The significance of biomarkers in patient selection Review emerging clinical data from paxalisib, a brain penetrant PI3K / mTOR inhibitorRead more
day: Day Two
PANEL DISCUSSION: Recognize the Financial Difficulty of Developing Glioblastoma Treatments and Moving Drugs to the Next Phase 11:00 am
Explore the challenges of funding development How can drug developers inspire and attract companies to invest in their novel preclinical glioblastoma development and pipeline? How can the industry come together to overcome the paucity of funding?Read more
day: Day Two